Hypertrophic Cardiomyopathy
Conditions
Keywords
Hypertrophic cardiomyopathy
Brief summary
This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.
Interventions
DRUGMavacamten
As per product label
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants ≥18 years of age. * Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. * Participants who consented to the use of their de-identified data, generated from information collected in the course of the program.
Exclusion criteria
• There are no
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participant demographics | Baseline |
| Participant clinical characteristics | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| Dose regimen of mavacamten treatment | Every 3-months up to 14 months |
| Titration patterns of mavacamten treatment | Up to 14 months |
| Mavacamten treatment duration | Up to 14 months |
Countries
Canada
Contacts
STUDY_DIRECTORBristol-Myers Squibb
Bristol-Myers Squibb
Outcome results
None listed